Updates are available Correction dated 2026-05-16

Article History

Received: 8 January 2026

Accepted: 10 March 2026

First Online: 30 March 2026

Change Date: 16 May 2026

Change Type: Update

Change Details: The original online version of this article was revised: The original published version of this article unfortunately contained mistakes. The authors identified an error in Table 1 where several tables are overlapping, making the final rows of all tables difficult or impossible to read. These corrections do not affect the scientific content, interpretation, or conclusions of the article. The authors apologize for any inconvenience caused to the readers.

Change Date: 16 May 2026

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s11882-026-01278-1

Declarations

:

: This article does not contain any studies with human or animal subjects performed by any of the authors.

: Author AID: has received speaker fees from GlaxoSmithKline, Sanofi and Regeneron Pharmaceuticals Inc., AstraZeneca, Viatris, Loafarma, Menarini, Organon, Uriach, Inmunotek, Leti, Diater and Optinose.Author ZA: she has no conflict of interest.Author MV: received remuneration for scientific advisory in the REAL Project from LETI Pharma and in the FARO Project from Astra-Zeneca, for participating in studies conducted by Orion Pharma and Pharmore Research and has also received honoraria as a speaker from LETI Pharma, Astra-Zeneca, GSK and Sanofi.Author IA declares to have received honoraria for consultancy and conferences from AstraZeneca, Viatris, Roche, Sanofi, GSK, MSD, Menarini, Salvat, Galenus Health, Olympus, Medtronic, and Novartis.Author JM: has received speaker fees from GlaxoSmithKline, Menarini, Merck Sharp & Dohme, Mylan-Meda Pharmaceuticals (Viatris), Novartis, Regeneron Pharmaceuticals Inc., Sanofi, UCB Pharma, and Uriach; clinical trial funding from Genentech-Roche, Regeneron Pharmaceuticals Inc., and Sanofi; research grants from Mylan-Meda Pharmaceuticals (Viatris) and Uriach; and advisory board fees from Genentech-Roche, Mylan-Meda Pharmaceuticals (Viatris), Novartis, Regeneron Pharmaceuticals Inc., Sanofi, and Uriach.

: We confirm that the figure and table are originals.

: JM is a Section Editor for the journal Current Allergy and Asthma Reports. He was not involved in the peer-review or handling of the manuscript. The authors have no other competing interests to disclose.